Abstract:Abstract Background: Recently, more and more treatment strategies for Hepatocellular carcinoma (HCC) have emerged, but the therapeutic effect is still not satisfactory. This study is aimed to explore the mechanism of Interleukin 35 (IL-35) in promoting the progression of liver cancer and to explore the application value of IL-35 in the treatment of HCC.Methods: We used clinical tissue microarray (TMA) immunohistochemistry (IHC) to explore the prognostic value of IL-35 expression in patients with HCC. The effect of IL-35 on the function of HCC was explored by functional experiments including wound-healing assay, transwell, cell counting kit-8, cell adhesion assay and endothelial tube formation assay in vitro and mouse xenografts in vivo. And flow cytometry was used to study the effect of IL-35 on infiltrating immune cells in tumor. The molecular mechanism of the function of IL-35 on the progression of HCC was explored by sequencing, ELISA, WB, PCR and other technical means. Finally, through in vivo tumor animal experiments to explore the value of anti-IL-35 antibody and combined with anti-PD-1 antibody in the treatment of liver cancer.Results: High expression of IL-35 in patients with HCC were identified to be associated with poor prognosis. And we have found that IL-35 facilitated tumor progression by affecting neutrophil infiltration, angiogenesis, and CD8+ T-cell infiltration in a mouse model. Additionally, on the one hand C-C motif chemokine ligand 3 (CCL3) has been found to be a key factor mediating the recruitment of neutrophils by IL-35, on the other hand fibroblast growth factor 2 (FGF2) secreting by neutrophil when stimulated by IL-35 was also found to be the core cytokine to promote intratumoral angiogenesis. And IL-35 was also discovered to facilitated the adhesion of tumor to endothelial cells, with neutrophils further enhancing this effect in vitro and vivo. More important, anti-IL-35 antibody was found to be a valid treatment for HCC in xenograft tumor model, and it could give full play to the curative effect of 1:1＞2 when combination therapy with PD-1 antibody.Conclusion: Our data show that the expression of IL-35 in patients with HCC is an important tumor promoting factor. The application of anti-IL-35 antibody and treatment combined anti-IL-35 antibody with anti-PD-1 antibody have potential therapeutic value in the treatment of liver cancer.

Gene Therapy For Hepatocellular Carcinoma Using Adenoviral Vectors Delivering A Gene Encoding Il-17a-Neutralizing Antibody Fragments

Adenovirus-mediated Tissue-Specific Cytosine Deaminase Gene Therapy for Human Hepatocellular Carcinoma with Different AFP Expression Levels.

Antitumor Effects Of Interleukin-18 Gene-Modified Hepatocyte Cell Line On Implanted Liver Carcinoma

E1a-Engineered Human Umbilical Cord Mesenchymal Stem Cells As Carriers and Amplifiers for Adenovirus Suppress Hepatocarcinoma in Mice

Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5

Interleukin-17f Suppresses Hepatocarcinoma Cell Growth Via Inhibition of Tumor Angiogenesis

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

DNA Polymerases as targets for gene therapy of hepatocellular carcinoma

Gene-viro-therapy Targeting Liver Cancer by a Dual-Regulated Oncolytic Adenoviral Vector Harboring IL-24 and TRAIL

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Interleukin 35 Activates Intratumor Neovascularization Via Enhanced Secretion of FGF2 in Hepatocellular Carcinoma Through The Recruitment of Neutrophils, and Blocking it Could Facilitate The Efficacy of The PD-1 Antibody

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

[Tumor-Targeting Expression of a New Tumor Suppressor Gene HCCS1 and Its Tumor-Selective Inhibitory Effects on Hepatocellular Carcinoma].

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus-Thymidine Kinase/ganciclovir Direct Intratumoral Gene Therapy of Hepatocellular Carcinoma

Multifunctional Gene Delivery Vectors Containing Different Liver-Targeting Fragments for Specifically Transfecting Hepatocellular Carcinoma (HCC) Cells

Adenovirus-Mediated Combined Anti-Angiogenic and Pro-Apoptotic Gene Therapy Enhances Antitumor Efficacy in Hepatocellular Carcinoma

Potent Anti-Hepatoma Efficacy of HCCS1 Via Dual Tumor-Targeting Gene-Virotherapy Strategy.

Gene Therapy Targeting Hepatocellular Carcinoma by A Dual-Regulated Oncolytic Adenovirus Harboring the Focal Adhesion Kinase Shrna

Antiangiogenesis Gene Armed Tumor‐targeting Adenovirus Yields Multiple Antitumor Activities in Human HCC Xenografts in Nude Mice

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells